News January 8, 2018 AUTM – FY2016 Licensing Survey More than ever, academic technology transfer is driving economic development. The number of invention disclosures… Super User 0 Love0
News January 8, 2018 Boehringer Ingelheim expands Venture Funds to €250m – European Biotechnology Originally, the BIVF was designed to put investments of up to €10-15m into early stage companies… Super User 0 Love0
News January 8, 2018 Bluefield Innovations thinks this JHU cancer research could become a new Baltimore company – Technical.ly Baltimore Cancer research helmed by a Johns Hopkins radiation oncology professor is the first to receive… Super User 0 Love0
News January 8, 2018 Personal Genome Diagnostics closes $75M Series B, plans second Baltimore office – Technical.ly Baltimore Canton-based Personal Genome Diagnostics closed on $75 million in Series B funding and plans to… Super User 0 Love0
News January 8, 2018 WellDoc Validates Potential of Its Digital Therapeutic, BlueStar®, to Significantly Reduce Healthcare Costs WellDoc®, a leading digital health company, announced today that its clinically proven hemoglobin A1C reductions… Super User 0 Love0
News January 8, 2018 ‘Hey, Dude, Where’s My Exclusivity?’: United Therapeutics, FDA Tussle – Bloomberg BNA Silver Spring, Md.-based United Therapeutics Corp. and the FDA are duking it out in court… Super User 0 Love0
News January 8, 2018 Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 2 dose ranging study… Super User 0 Love0
News January 8, 2018 Xconomy: San Diego Life Sciences 2022: Photos and Takeaways Making predictions can be a tricky business. Nevertheless, Xconomy recently brought together some of San… Super User 0 Love0
News January 8, 2018 Trump FDA Chief Scott Gottlieb Isn’t Pharma’s BFF After All – Bloomberg Gadfly Scott Gottlieb seems like the pharmaceutical industry's idea of a dream FDA Commissioner, with pharma… Super User 0 Love0
News January 8, 2018 Ex-Pfizer CEO’s startup Centrexion gets $67M for PhIII painkiller – Endpoints News Centrexion Therapeutics, a Boston-based startup led by ex-Pfizer CEO Jeff Kindler, just raised $67 million… Super User 0 Love0